Methanol extract of the seaweed Gloiopeltis furcata induces G2/M arrest and inhibits cyclooxygenase-2 activity in human hepatocarcinoma HepG2 cells

Phytotherapy Research

Volumn 21, Issue 1, 2007, Pages 52-57

  Bae, Song Ja ^a   Choi, Yung Hyun ^b,c  

^a Silla University   (South Korea)

^b Dong Eui University   (South Korea)

^c Dong Eui University   (South Korea)

Author keywords

COX 2; G2 M arrest; Gloiopeltis furcata; HepG2; p21

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLOIOPELTIS FURCATA EXTRACT; MESSENGER RNA; METHANOL EXTRACTION RESIDUE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; ENZYME ACTIVITY; GLOIOPELTIS FURCATA; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL; PROTEIN EXPRESSION; SEAWEED;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEAWEED;

GLEIOPELTIS FURCATA;

EID: 33846616246     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2020     Document Type: Article

References (29)

1. Abraham RT. 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196.
2. Anderson WF, Umar A, Viner JL et al. 2002. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm 8: 1035-1062.
3. Baus F, Gire V, Fisher D et al. 2003. Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J 22: 3992-4002.
4. Booher RN, Holman PS, Fattaey A. 1997. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 272: 22300-22306.
5. Carper J. 1989. Seaweed, or kelp. In The Food Pharmacy. Bantam Books: New York, 264-268.
6. Cheng T. 2004. Cell cycle inhibitors in normal and tumor stem cells. Oncogene 23: 7256-7266.
7. Dulic V, Stein GH, Far DF et al. 1998. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18: 546-557.
8. El-Deiry WS, Tokino T, Velculesco VE et al. 1992. WAF1, a potential mediator of p53 suppression. Cell 75: 817-825.
9. Elledges SJ, Harper JW. 1994. Cdk inhibitor: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852.
10. Hiqashi-Okaj K, Otani S, Okai Y. 1999. Potent suppressive effect of a Japanese edible seaweed, Enteromorpha prolifera (Sujiao-nori) on initiation and promotion phases of chemically induced mouse skin tumorigenesis. Cancer Lett 140: 21-25.
11. Lee MH, Yang HY. 2001. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58: 1907-1922.
12. Ling YH, el-Naggar AK, Priebe W et al. 1996. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49: 832-841.
13. McGowan CH, Russell P. 1993. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 12: 75-85.
14. Okai Y, Higashi-Okai K, Nakamura S et al. 1994. Suppressive effects of the extracts of Japanese edible seaweeds on mutagen-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002) and tumor promotor-dependent ornithine decarboxylase induction in BALB/c 3T3 fibroblast cells. Cancer Lett 87: 25-32.
15. Oshima M, Taketo MM. 2002. COX selectivity and animal models for colon cancer. Curr Pharm Des 8: 1021-1034.
16. Park SY, Jung BM, Choi YH et al. 2005. Growth inhibition effects of cancer cell lines by Gloiopeltis furcata fractions in vitro. J Korean Soc Food Sci Nutr 34: 771-775.
17. Sargent JM. 2003. The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results Cancer Res 161: 13-25.
18. Sherr CJ. 1996. Cancer cell cycles. Science 274: 1672-1677.
19. Smith WL, DeWitt DL, Garavito RM et al. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182.
20. Soh JW, Weinstein IB. 2003. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 37: 261-285.
21. Stratton MS, Alberts DS. 2002. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Huntingt) 16: S37-S51.
22. Tchou WW, Rom WN, Tchou-Wong KM. 1996. Novel form of p21(WAF1/CIP1/SDII) protein in phorbol ester-induced G2/M arrest. J Biol Chem 271: 29556-29560.
23. Umar A, Viner JL, Anderson WF et al. 2003. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 26: S48-S57.
24. Waldman T, Kinzler KW, Vogelstain B. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190.
25. Xiong Y, Hannon G, Zhang H et al. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
26. Yamamoto I, Maruyama H. 1985. Effect of dietary seaweed preparations on 1,2-dimethylhydrazine-induced intestinal carcinogenesis in rats. Cancer Lett 26: 241-251.
27. Yamamoto I, Maruyama H, Moriguchi M. 1987. The effect of dietary seaweeds on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats. Cancer Lett 35: 109-118.
28. WAF1/CIP1 expression by p53-independent pathways. Oncogene 12: 1557-1564.
29. Zhang W, Grasso L, McClain CD et al. 1995. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668-674.